Cyclerion to Merge With Korsana in Reverse Takeover Backed by $380 Million

Overview

• A merger announced Wednesday combines Cyclerion with private Korsana in an all-stock deal that effectively makes Korsana the public company.
• Existing Cyclerion holders are set to own about 1.5% of the combined firm, while Korsana investors would hold roughly 98.5%, and the company plans to trade on Nasdaq as KRSA.
• Korsana raised about $380 million in an oversubscribed private round led by Fairmount and Venrock with Janus Henderson, J.P. Morgan, and Sanofi Ventures, providing runway through 2029.
• The lead drug, KRSA-028, targets amyloid beta for Alzheimer’s and uses a transferrin-receptor “shuttle” for better brain delivery with planned under-the-skin dosing, with Phase 1 data expected mid-2027 and early proof-of-concept by year-end 2027.
• CYCN shares jumped more than 160% in pre-market trading after the news, and closing is targeted for Q3 2026 pending stockholder votes, SEC clearance, and other customary approvals.